and the first to the state of the state of the state of the states of the states of the station of the states of the states of the station of the state of the state of the te I 0 I Image Source Repare Therapeutics Inc. (NASDAQ:RPTX) is gearing up to report results from its phase 1 MYTHIC trial, which is using lunresertib [RP-6306] in combination with camonsertib [RP-3500] for the treatment of patients with platinum-resistant ovarian and endometrial cancers. This will be a major inflection point because it w ...